Compare Kohl's Corporation (KSS) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kohl's Corporation vs Natera Inc. Common Stock — how do they compare? Kohl's Corporation trades at $21.2 (market cap $2.40B), while Natera Inc. Common Stock trades at $392.78 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 23.8× Kohl's Corporation's market cap, and Kohl's Corporation pays a 2.36% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kohl's Corporation for 48 Days and Natera Inc. Common Stock for 0 Days on average.
| KSS | NTRA | |
|---|---|---|
Market Cap | $2.40B | $57.03B |
Volume | 3,788,378 | 1,131,157 |
Sector | Consumer Cyclical | Health |
52-Week High | $24.71 | $425.64 |
52-Week Low | $11.72 | $179.42 |
Typical Hold Time | 48 Days | 0 Days |
Enterprise Value | $8.00B | $56.18B |
Dividend Yield | 2.36% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kohl's (KSS) trades at $21.10, down 0.33% on the day, with a bullish technical signal from moving averages and a low valuation profile (P/E 9.06, P/S 0.16). Recent earnings beats in Q4 2025 and Q1-Q2 2026, alongside a raised full-year outlook, highlight improving operational momentum, though revenue has declined from $19.4B in 2022 to $16.2B in 2025. The company maintains a dividend, with the next payment of $0.13 scheduled for September 23, 2026.
The stock presents a value opportunity with attractive multiples and positive earnings surprises, but faces headwinds from 18 consecutive quarters of sales declines and competitive pressures. Analyst sentiment is mixed with a 30% buy rating, and the consensus price target of $15.50 implies downside risk from current levels. Execution on holiday sales and margin stabilization are critical for sustaining the recent rebound.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kohl's Corporation
Kohl's operates 1,165 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 27% of its 2021 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
Read more on KSS →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
